Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer by Caterina Peraldo-Neia et al.
RESEARCH ARTICLE Open Access
Epidermal Growth Factor Receptor (EGFR)
mutation analysis, gene expression profiling
and EGFR protein expression in primary
prostate cancer
Caterina Peraldo-Neia1,2*, Giorgia Migliardi1, Maurizia Mello-Grand2, Filippo Montemurro3, Raffaella Segir2,
Ymera Pignochino1, Giuliana Cavalloni1, Bruno Torchio4, Luciano Mosso4, Giovanna Chiorino2, Massimo Aglietta1,3
Abstract
Background: Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to the tyrosine
kinase inhibitors (TKi), gefitinib and erlotinib. We analysed EGFR expression, EGFR mutation status and gene
expression profiles of prostate cancer (PC) to supply a rationale for EGFR targeted therapies in this disease.
Methods: Mutational analysis of EGFR TK domain (exons from 18 to 21) and immunohistochemistry for EGFR were
performed on tumour tissues derived from radical prostatectomy from 100 PC patients. Gene expression profiling
using oligo-microarrays was also carried out in 51 of the PC samples.
Results: EGFR protein overexpression (EGFRhigh) was found in 36% of the tumour samples, and mutations were
found in 13% of samples. Patients with EGFRhigh tumours experienced a significantly increased risk of biochemical
relapse (hazard ratio-HR 2.52, p=0.02) compared with patients with tumours expressing low levels of EGFR
(EGFRlow). Microarray analysis did not reveal any differences in gene expression between EGFRhigh and EGFRlow
tumours. Conversely, in EGFRhigh tumours, we were able to identify a 79 gene signature distinguishing mutated
from non-mutated tumours. Additionally, 29 genes were found to be differentially expressed between mutated/
EGFRhigh (n=3) and mutated/EGFRlow tumours (n=5). Four of the down-regulated genes, U19/EAF2, ABCC4, KLK3
and ANXA3 and one of the up-regulated genes, FOXC1, are involved in PC progression.
Conclusions: Based on our findings, we hypothesize that accurate definition of the EGFR status could improve
prognostic stratification and we suggest a possible role for EGFR-directed therapies in PC patients. Having been
generated in a relatively small sample of patients, our results warrant confirmation in larger series.
Background
Prostate cancer (PC) is among the most frequently diag-
nosed solid tumours in men, and the metastatic forms
still represent the second leading cause of cancer-related
death [1,2]. Treatment of PC by radical prostatectomy,
radiotherapy and anti-androgen therapy results in long
term survival in patients with localized and androgen-
dependent PC. By contrast, hormone-refractory prostate
cancer (HRPC) forms are associated with disease relapse
and poor patient survival [3,4]. At present, increasing
serum prostate-specific antigen (PSA) levels following
treatment of primary PC is used to identify PC bio-
chemical relapse, a condition that anticipates clinically
detectable tumour progression. The identification of
novel biomarkers that predict the risk of relapse or that
could be used as therapeutic targets is needed.
The molecular mechanisms responsible for PC devel-
opment, progression and hormone-independence are
not clear yet. Several findings suggest that alterations of
different pathways involving growth factor receptors
play a role in this multistep process [5,6]. In particular,
the Epidermal Growth Factor Receptor (EGFR) is
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frequently overexpressed in PC and this is associated
with a more aggressive clinical outcome. EGFR overex-
pression has also been linked to the transition from
androgen-responsiveness to the androgen-independent/
hormone-refractory phenotype [7,8]. Furthermore, pre-
clinical data have suggested that the EGFR signalling
pathway can activate the androgen receptor under con-
ditions of clinical androgen deprivation [9]. EGFR has
thus assumed considerable importance, due to overex-
pression in different tumour types and to its role as a
drug target. A variety of anti-EGFR drugs are currently
Food and Drug Administration-approved or under eva-
luation in clinical trials. These drugs include small inhi-
bitory molecules such as gefitinib or erlotinib, as well as
antibodies such as cetuximab and panitumumab. Gefiti-
nib is an oral anilinoquinazolone compound that blocks
the EGFR tyrosine kinase (TK) activity [10] resulting in
the inhibition of downstream signalling pathways. Clini-
cal evidence, mostly deriving from non small cell lung
cancer (NSCLC) patients, demonstrated that activating
mutations in the EGFR TK domain (exons from 18 to
21) predict response to gefitinib [11].
A recent study identified 4 novel missense mutations
in exons 19, 20 and 21 of the EGFR TK domain in Kor-
ean and Caucasian PC patients. Three of them, G735S,
G796S and E804G, led to an oncogenic activation pro-
moting cell proliferation and invasion [12].
Preclinical studies have shown activity of gefitinib
against PC cell lines and xenografts [13]. In a phase I
clinical trial, 252 patients with different solid tumours,
including 28 patients with HRPC, received oral gefitinib
[14]. One patient with HRPC had a measurable reduc-
tion of disease in a lymph node metastasis, palliation of
disease-related pain, and a reduction in PSA [15]. In
another randomized phase II clinical trial 82 HRPC
patients were treated with prednisone plus gefitinib or
prednisone plus placebo [16]. This study showed limited
antitumour activity of gefitinib in HRPC patients. How-
ever, patients were not selected on the basis of EGFR
status. At present, no clinical data are available on
EGFR-mutated PC patients treated with gefitinib.
In an effort to provide a rationale for further studies
of targeted therapies in PC, we set out to analyze EGFR
protein expression, EGFR mutations and their possible
correlations with clinical parameters and outcomes. For




One hundred glyofixx-fixed, paraffin-embedded PC
specimens were retrieved after radical prostatectomy in
100 PC patients. According to the availability of fresh
frozen tumour material, different subsets of the initial
100 patients selected for this analysis were studied.
Immunohistochemistry and mutational analysis were
performed in all the samples from 100 patients.
Fifty patients had tumour samples stored at -80°C and
were submitted to gene profiling. For one of these
patients, two different tumour samples were available.
Therefore, the total number of samples submitted to
gene profiling was 51.
The patients were of Italian origin and were diagnosed
at ASL (Azienda Sanitaria Locale) 12, Hospital of Biella.
To classify tumours according to grade, we used the
definition proposed by Franiel et al [17]. Tumours with
a Gleason Score from 4 to 6 were considered low grade
and those with a Gleason Score from 7 to 9 were con-
sidered high grade.
DNA extraction and direct sequencing
For all the specimens, it was possible to select tumour
areas and extract DNA for EGFR mutational analysis.
Genomic DNA was extracted from deparaffinised
tumour tissue using the QIAamp DNA Mini Kit (Qia-
gen, Milan, Italy) following the manufacturer’s instruc-
tions. The TK domain of EGFR coding sequence, from
exon 18 to 21, was amplified by using primers and
nested PCR conditions as previously described by Lynch
et al [18]. PCR products were purified by QIAquick
PCR purification kit (Qiagen) and sense and antisense
sequences were obtained by using forward and reverse
internal primers, respectively. Each exon was sequenced
using the BigDye Terminator Cycle sequence following
the PE Applied Biosystem strategy and Applied Biosys-
tems ABI PRISM3100 DNA Sequencer (Applied Biosys-
tem, Forster City, CA). All mutations were confirmed by
performing two independent PCR amplifications.
Immunohistochemistry
EGFR protein expression was evaluated on the entire
cohort. Tissue sections (3 μm thick) were mounted on
pre-coated slides, deparaffinised with xylene and rehy-
drated with graded ethanol. Endogenous peroxidase was
blocked with Peroxidase Blocking Solution (DAKO, CA,
USA) for 5 minutes. Sections were then incubated with
primary antibody for EGFR (1:200, Clone: 31G7, Mouse
anti-Human, Zymed) for one hour at room temperature.
The reaction was visualised using EnVision staining kit
(DAKO). Sections were counterstained with hemallume.
About 100 cells were counted in three different fields.
All slides were independently evaluated by two patholo-
gists (L.M. and B.T.). Discordant cases were reviewed a
third time and a consensus was reached. Basal EGFR
expression (EGFRlow) was defined as 10-49% of tumour
cells staining positively for EGFR. High EGFR expression
(EGFRhigh) was defined as ≥50% of tumour cells staining
positively for EGFR.
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Microarray analysis
Gene expression profiling was evaluated for 51 samples
from 50 patients (two specimens were analysed for one
patient) as previously described [19]. Briefly, total RNA
was isolated from sections of frozen tissues obtained
from 50 radical prostatectomies collected between 2003-
2005, using TriReagent (Sigma, St. Louis, MO, USA).
A commercially available RNA sample from 32 normal
prostates pooled from Caucasian males (ages: 21-50),
constituted the prostate RNA Reference (Clontech,
Mountain View, CA, USA). RNA quantity was evaluated
by Bioanalyzer 2100 (Agilent Technologies, Palo Alto,
CA, USA). Following the isolation procedure, mRNA
was amplified starting from 5 μg of total RNA using
MessageAmp aRNA Amplification kit (Ambion Inc.
Austin TX, USA). Amino-allyl modified nucleotides
were incorporated during the overnight in vitro tran-
scription step according to the manufacturer’s protocol.
Labeling was performed using NHS (N-hydroxysuccini-
midyl) ester Cy3 or Cy5 dyes (GE Healthcare Europe
GMBH, Upsala-Sweden) able to react with the modified
RNA. At least 5 μg of aaRNA for each sample were
labeled and then purified with columns; 0.75 μg of
labeled aaRNA for each sample were then hybridised.
The Dye-Swap replication procedure was applied, in
order to increase accuracy. Samples were hybridised on
22K human oligo-glass arrays, (Agilent Technologies).
Arrays were scanned by Agilent scanner. Images obtained
were analysed by the Feature Extraction software Agilent
(version 9.5) and the text files were then processed using
the Bioconductor package Limma (Linear models for
microarray analysis). Class comparison and unsupervised
hierarchical clustering were carried out using MeV (Multi
Experiment Viewer) version 4.1 (http://www.tm4.org). In
particular, non parametric testing (Wilcoxon, Rank Sum)
was adopted for feature selection. Gene Ontology analysis
was performed using the Database for Annotation, Visua-
lization and Integrated Discovery (DAVID tool), (http://
david.abcc.ncifcrf.gov).
Real time quantitative PCR (qRT-PCR)
RNA was extracted and transcribed into cDNA using
High capacity cDNA reverse transcription kit (PE
Applied Biosystem). cDNA was then used for amplifica-
tion of ABCC4, ANXA3, FOXC1, KLK3, U19 genes and
PGK gene (housekeeping gene) with the following speci-
fic primers: FW ABCC4 5’-AGAGGGTGTCAGAGG-
CAATC-3’, RV ABCC4 5’-CATCAAGTAGCAAAAA
GGTCT-3’; FW ANXA3 5’- GTTGGACACCGAGGAA
CAGT, RV ANXA3 5’- GCTGTGCATTTGACCTC-
TCA-3’; FW FOXC1 5’- TAGCTGTCAAATGGCCTTC,
RV FOXC1 5’ - TAGTTCGGCTTTGAGGGTGT - 3’;
FW KLK3 5’-TCCCAGACGTGGATTGGT-3’, RV
KLK3 5’-CAGGGTTGGGAATGGTTCT-3’; FW U19
5’- CAGGGAATTGTGTCTCAGGAC-3’, RV U19 5’-
GGCCACTGTTGTCTCGAAAT - 3’. Real-time PCR
was carried out in triplicate in optical grade 96-well
plates with 5 μl SYBR Green Master mix (PE Applied
Biosystems), 12.5 μM of each primer, and 35 ng of
cDNA in a volume of 60 μl. Thermal cycling was per-
formed using the Applied Biosystems 7300 real-time
PCR system with the following conditions: 95°C for 10
min, 40 cycles at 95°C for 15 sec, 60°C for 1 min. Rela-
tive quantitation of target genes was obtained by using
the comparative cycle threshold (Ct) methods as pre-
viously described [20]. Briefly, to calculate the relative
expression of the target gene mRNA normalized to
PGK, the average of target Ct was subtracted from the
average of PGK Ct (ΔCt). The amount of target, normal-
ized to an endogenous reference and relative to a cali-
brator (fold-change) is given by 2-ΔΔCt where the
calculation of ΔΔCt involves subtraction by the ΔCt
calibrator value (EGFRlow). Assuming that ΔCt = 3.3
corresponds to a 10-fold difference of expression
between PGK and the target, as calculated from log 10,
ΔCt results were divided by 3.3 and represented on a
logarithmic scale.
Statistics
Comparisons between dichotomous variables were per-
formed by the Fisher’s exact test.
Time to biochemical relapse (TTBR) was calculated
from the date of prostate cancer surgery to that of bio-
chemical relapse, defined as a serum PSA level > 0.2 ng/
ml in at least 2 subsequent measurements performed
≥3 months from prostatectomy [21]. Univariate compar-
isons of time to biochemical relapse (TTBR) according
to EGFR immunohistochemical status, mutational status,
disease stage and Gleason Score group were performed
by Cox Proportional Hazards analysis and by drawing
Kaplan-Meier curves, which were compared by the log-
rank test. If more than one factor resulted significantly
associated with TTBR at the p < 0.10 level, a multivari-
ate Cox Proportional Hazards model including the sig-
nificant factors was studied.
Results
Clinical parameters and EGFR expression on PC
specimens
The characteristics of 100 patients with tumours avail-
able for analysis of EGFR expression and mutations are
summarized in table 1 and in additional file1, table S1.
One hundred PC samples were evaluated for EGFR
protein expression by immunohistochemistry. EGFR
immunostaining was predominantly found in the mem-
brane and the cytoplasm. EGFR was expressed at low
levels in normal glands in 90 out of 100 samples (90%),
and in 36 out of 100 cases (36%), tumour areas were
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classified as overexpressing EGFR (EGFRhigh) (additional
file 1, table S1). Figure 1 provides an example of the
immunohistochemical pattern of EGFR protein expres-
sion in normal and tumour tissues. The impact of clinical
and pathological variables on biochemical relapse was
studied in a subgroup of 59 patients who underwent reg-
ular visits at the same Institution where they had under-
gone surgery, and for whom we had detailed follow-up
information. The median follow-up for these patients was
207 months (range 16-366 months). The other 41
patients, who underwent follow-up visits at different
Institutions after surgery, were excluded from this analy-
sis because of incomplete or missing follow-up informa-
tion. Twenty-eight out of 59 patients experienced
biochemical relapse (overall median TTBR 84 months).
Univariate analyses revealed a significant effect of EGFR
immunohistochemical status on TTBR (figure 2). Median
TTBR was 104 and 30 months for patients with EGFRlow
and EGFRhigh tumours, respectively (hazard ratio-HR
2.53, p= 0.02). Furthermore, a strong trend towards a
worse median TTBR was observed in patients with high
vs low Gleason Score tumours (63 months vs not reached
respectively, HR 2.80, p= 0.10) (figure 3). Neither median
age nor tumour stage at diagnosis correlated significantly
with TTBR. When EGFR immunohistochemical status
and Gleason Score were entered together in a Cox Pro-
portional Hazards model, results did not change signifi-
cantly, suggesting that EGFR immunohistochemical
status (multivariate HR 2.67, p = 0.01) and Gleason Score
(multivariate HR 3.04, p = 0.08) were independent
predictors of TTBR.
Mutational analysis
Of 100 patients who underwent surgical resection of their
tumours, 13 presented point mutations (13%) in the TK
domain of EGFR (Table 1). Specifically, we detected
2 point mutations in exon 19: T751I, previously
described in erlotinib responsive NSCLC patients [22]
and R748K, described in soft tissue sarcomas [23]. In
exon 20, we found 5 point mutations: E804G, already
described in PC [12], Q820R, G796V, P782L, F788L, not
previously described. In exon 21, 4 novel missense muta-
tions were revealed: L828M, F856Y, F856L, A839V, and
2 previously described, G863D, in partial gefitinib
responsive NSCLC patients [24], and V851I, described in
gefitinib-unresponsive NSCLC patients [25]. No point
mutations were identified in exon 18. Table 2 sum-
marised all mutations found. Fifty-eight out of 100
specimens had the same silent mutation, both in hetero-
zygotic and in homozygotic status, on the codon 787 in
exon 20. No mutations were found in the normal coun-
terpart. The frequency of mutations was not significantly
different in EGFRhigh vs EGFRlow tumours (6% vs 7%,
respectively, p=0.50); all mutated samples had a high
Gleason Score (13%), but no statistically significant asso-
ciation was revealed (p= 0.12). Finally, the mutation sta-
tus had no significant impact on TTBR, although it
should be noted that only 5 patients with mutated
tumours were included in this analysis.
Gene profiling
Gene expression profile analysis was performed in
51 fresh frozen samples from 50 patients.
Nineteen samples were EGFRhigh and 32 displayed a
basal expression of EGFR. Comparison between these
two classes did not give significant results in terms of
differentially expressed genes. Analysing only the EGFR-
high samples, a 79-gene signature (40 up-regulated and
39 down-regulated) distinguished EGFRhigh/mutated
samples from EGFRhigh/WT samples (figure 4 and addi-
tional file 2, table S2). In order to identify in which pro-
cesses these genes are implicated, a Gene Ontology
analysis was performed. Three biological processes are
involved, namely cellular lipid metabolism, primary
metabolism and the inflammatory response (Table 3).
For 8 of the 13 cases harbouring an EGFR TK mutation
fresh frozen tissue was available for gene expression
analysis. In these samples we could identify a panel of
29 genes which were differentially expressed between
EGFRhigh and EGFRlow tumours (Table 4). Figure 5
shows the significant distinction of the two classes
obtained from this 29-gene signature.
In particular, 5 of these genes are involved in prostate
cancer progression and most of them are AR (androgen
receptor) regulated. Among them, U19, ABCC4, ANXA3
and KLK3 are less expressed in EGFRhigh samples. One of
the more expressed genes in EGFRhigh samples is FOXC1, a
member of forkhead transcription factors (FOX) (figure 6).
Quantitative RT-PCR on 8 EGFR mutated samples con-
firmed results obtained by microarray analysis on the five
differentially expressed genes discussed above (figure 7).
Table 1 Patient characteristics
Variable Value (%) n = 100
Median age, years (range) 66 (53-74)





G 4 1 (1)
G 5 5 (5)
G 6 12 (12)
G 7 52 (52)
G 8 22 (22)
G 9 8 (8)
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Figure 1 Different EGFR pattern of expression in normal and PCs tissues revealed by immunohistochemistry. A: negative control: lobular
breast carcinoma not expressing EGFR. B: positive control: colon carcinoma expressing high levels of EGFR. C: normal prostate tissue not
expressing EGFR. D: normal prostate tissue expressing EGFR. E: PC tissue not expressing EGFR. F-G: PC tissues expressing different pattern of
EGFR. (Magnification 10X).
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Discussion
In this study, we were interested in analysing EGFR
expression and somatic mutations of its TK domain in
prostatectomy specimens from patients with operable PC.
Metastatic PC represents a challenge for the oncologist
and novel therapeutic strategies are therefore warranted,
especially when it evolves into the hormone-refractory
status. Previous observations have pointed to deregulated
EGFR function as a potentially relevant phenomenon in
sustaining PC progression and the development of a hor-
mone-refractory phenotype [7,8]. However, EGFR target-
ing agents have shown limited clinical activity in clinical
trials conducted in PC patients [16,26-29]. Notably, these
studies enrolled unselected patients with respect to EGFR
status. EGFR targeting with TKIs, such as gefitinib and
erlotinib [10,30], has proven successful in molecularly
defined subsets of patients with non-small cell lung can-
cer (NSCLC), where specific mutations of the EGFR tyro-
sine kinase domain, but not protein expression, were
predictive of the clinical efficacy [31]. Defining the rela-
tionship between EGFR status and the clinical behaviour
of PC may therefore help define a possible therapeutic
role of EGFR inhibitors in this patient subset.
In our study, we found that EGFR was expressed at
normal levels in healthy prostate cells in 90% of the
surgical specimens. In tumour areas, EGFR overexpres-
sion was found in 36 patient specimens (36%). In line
with the literature, we confirmed that EGFR overex-
pression was significantly associated with biochemical
relapse. Furthermore, although confirmation in a larger
dataset is needed, EGFR overexpression predicts TTBR
independently from Gleason Score, which is an estab-
lished prognostic factor in this disease.
Having only analysed an Italian Caucasian population,
and due to a small sample size, this incidence of EGFR
overexpression is difficult to generalize. It has been
shown, for example, that Afro-American patients
affected by PC expressed EGFR at higher levels than
Caucasian patients [32].
Figure 2 Kaplan-Meier estimates of time to biochemical
relapse according to EGFR immunohistochemical status. The
solid line represents patients with EGFRlow tumours and the dashed
line represents those with EGFRhigh tumours. Median time to
biochemical relapse was 104 and 30 months for patients with
EGFRlow and EGFRhigh tumours, respectively (log-rank test, p=0.01).
Figure 3 Kaplan-Meier estimates of time to biochemical
relapse according to Gleason Score category. The solid line
represents patients with low score tumours and the dashed line
represents those with high score tumours. Median time to
biochemical relapse was not reached for patients with low score
tumours and was 63 months for those with high score tumours
(log-rank test, p=0.08).
Table 2 Summary of EGFR mutations found in our work
and respective references if previously described
EXON 19
Patient 50 T751I Described by Tsao et al
Patient 63 (P51) R748K Described by Dobashi et al
EXON 20
Patient 12 E804G Described by Cai et al
Patient 64 (AA65) Q820R Novel mutation
Patient 72 (CC62) P872L Novel mutation
Patient 73 (CC75) F788L Novel mutation
Patient 99 G796V Novel mutation
EXON 21
Patient 2 V851I Described by Cappuzzo et al
Patient 8 G863D Described by Bell et al
Patient 11 A839V Novel mutation
Patient 40 L828M Novel mutation
Patient 56 F856Y Novel mutation
Patient 88 F856L Novel mutation
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Mutational analysis revealed that 13 out of 100
patients had tumours carrying mutations in the EGFR
TK domain. Two of these mutations (exon 19 T751I
and exon 21 G863D) have been previously identified as
predictors of response to small TKIs in NSCLC patients
[22,23]. Another one, the V851I mutation, has been pre-
viously described in NSCLC patients refractory to TKIs
treatment [24]. The E804G mutation that we found on
exon 20, was previously described by Cai et al. in PC
specimens [12]. These authors identified four novel
Figure 4 Cluster analysis applied to EGFRhigh: a 79-gene signature separated EGFRhigh/mutated samples(N34, CC62, CC75)from
EGFRhigh/WT samples. (G70, C25, A9, E45, M26, AA88, AA90, BB36, CC17, CC41, CC87, CC91, G62, P55, Q65, W28). (N34, CC62, CC75, G70, C25,
A9, E45, M26, AA88, AA90, BB36, CC17, CC41, CC87, CC91, G62, P55, Q65, W28 referred to patients code as in additional file 1, table S1).
Table 3 Gene Ontology of the 79 modulated probes in EGFRhigh/mutated compared to EGFRhigh/WT
Category Term P-value Genes (Entrez ID
GOTERM_BP_ALL GO:0044255~cellular lipid metabolic process 0.03 122970, 2581, 54884, 23396,
2170, 259230
GOTERM_BP_ALL GO:0044238~primary metabolic process 0.07 134, 122970, 5127, 1478,
4520, 2581, 7596, 54884,
115426, 10730, 4968, 4762,
7372, 6944, 26292, 23396,
84203, 8908, 6613, 2170,
4325, 259230, 51582, 6815,
63931, 6997, 10073, 5689,
1676, 5786
GOTERM_BP_ALL GO:0006954~inflammatory response 0.09 134, 8455, 6369, 259230
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somatic mutations in the EGFR tyrosine kinase domain
of PC patients: G735S, G796S, E804G and R841K. They
investigated their oncogenic potential by establishing
stable clonal NIH3T3 cells expressing these mutations
and WT EGFR to determine their ability to increase cell
proliferation and invasion. Amongst them, the E804G
mutation resulted as the most active and significant
somatic missense mutation in the TK domain, being
associated with the greatest growth potential, and by the
highest transformation and invasion ability [12]. Q820R,
G796V, P782L, F788L, A839V, L828M, F856Y, F856L
are novel mutations and further exploration of their
effect on the activation of the downstream EGFR path-
way is warranted.
Gene expression profile analysis failed to identify
genes that were differently expressed in tumours with
high vs low levels of EGFR, or in EGFR mutated vsnon
mutated tumours. The small sample size and the het-
erogeneity of mutations may have limited the ability of
this analysis to capture significant gene expression pat-
terns. Interestingly, when we restricted the analysis to
EGFR-overexpressing tumours (EGFRhigh), we could
identify a 79 gene signature distinguishing mutated
from non mutated samples. Three biological processes
(lipid and primary metabolic processes and the inflam-
matory response) are altered and they may help discri-
minate between the two classes. Further studies could
reveal the role of EGFR mutations in the regulation of
these specific genes. Another 29 genes were found to
be differently modulated in mutated tumours accord-
ing to their EGFR expression level (high vs low). Four
of the genes that were expressed at lower levels in
Table 4 Differentially expressed genes selected in samples mutated for EGFR TK domain
EntrezGene Gene Name Description Log10Ratio *
2952 GSTT1 Glutathione S-transferase theta-1 ↓
10257 ABCC4 Multidrug resistance-associated protein 4 ↓
1657 DMXL1 DmX-like protein 1 ↓
25800 SLC39A6 Zinc transporter ZIP6 Precursor ↓
55840 EAF2 ELL-associated factor 2 ↓
354 KLK3 Prostate-specific antigen Precursor (PSA) ↓
81035 COLEC12 Collectin-12 (Collectin placenta protein 1) ↓
10788 IQGAP2 Ras GTPase-activating-like protein ↓
123036 MTAC2D1 Tandem C2 domains nuclear protein ↓
3150 HMGN1 Non-histone chromosomal protein HMG-14 ↓
55359 STYK1 Tyrosine protein-kinase ↓
64757 MOSC1 MOSC domain-containing protein 1, mitochondrial Precursor ↓
5269 SERPINB6 Serpin B6 (Placental thrombin inhibitor) ↓
1066 ANXA3 Annexin A3 ↓
652708 CES1 Liver carboxylesterase 1 Precursor ↑
220164 DOK6 Docking protein 6 (Downstream of tyrosine kinase 6) ↑
2296 FOXC1 Forkhead box protein C1 ↑
219699 UNC5B etrin receptor UNC5B Precursor ↑
2070 EYA4 Eyes absent homolog 4 ↑
10964 IFI44L Interferon-induced protein 44-like ↑
678 ZFP36L2 Butyrate response factor 2 ↑
64710 NUCKS1 Nuclear ubiquitous casein and cyclin-dependent kinases substrate (P1) ↑
10365 KLF2 Krueppel-like factor 2 ↑
1783 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 ↑
79884 MAP9 Microtubule-associated protein 9 ↑
2813 GP2 Pancreatic secretory granule membrane major glycoprotein GP2 Precursor ↑
22888 UBOX5 RING finger protein 37 ↑
* Log10Ratio: logarithm (base 10) of the ratio between PC sample and prostate reference expression values. ↑: up regulated gene. ↓: down-regulated gene.
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EGFRhigh samples have been previously linked to PC.
The expression of U19/EAF2 in xenograft prostate
tumours markedly induced apoptosis and inhibited
tumour growth in vivo [33]. Moreover, the disruption
of androgen-dependent growth regulation via U19/
EAF2 down-regulation has been found to be com-
monly associated with PC progression. These observa-
tions suggest that U19/EAF2 may act as a tumour
suppressor gene. Another finding revealed that the
prostate specific ATP-binding cassette transporters
ABCC4 was found to be expressed at higher levels in
PC than in benign prostate tissue and decreased
expression was found after androgen ablation [34].
Zhao et al. found a marked reduction in KLK3 expres-
sion levels in androgen-independent, compared
with androgen-sensitive PC cell lines [35]. Finally, it
was demonstrated that ANXA3 protein expression
decreases from benign prostatic hypertrophy to loca-
lised pre-neoplastic lesions [36]. Among the genes that
we found to be expressed at higher levels in EGFRhigh
tumours, one has been previously linked to PC.
FOXC1, a member of forkhead transcription factors
(FOX), was found to be expressed at significantly high
levels in androgen-independent PC xenografts [37].
Our data, which are mostly concordant with previous
observations, suggest that EGFR overexpression may
result in a more aggressive tumour behaviour [38],
through deregulated function of these genes.
We acknowledge that these are preliminary data based
on a small number of cases [12,39], with consequent
limitations in the generalizability of our results. For
example, the prevalence of EGFR mutations that we
have found is in the range of that reported by other
authors analyzing PC or cholangiocarcinoma [12,40].
Compared to other EGFR-driven diseases like NSCLC,
where the prevalence of EGFR mutations has been
reported to be as high as 30%, in PC EGFR mutations
are less frequent. A larger sample size is therefore
required to collect sufficient mutated cases to perform a
more powerful analysis of the impact of mutations on
prognosis or other biological features of tumours. Simi-
larly, a larger number of mutated cases may result in
the ability of gene expression analysis to capture signifi-
cant gene expression patterns. In our study, because of
the limited availability of fresh frozen material, the gene
expression profile analysis was feasible in tumour sam-
ples from just 8 patients.
In summary, we found that 36% of the patients in this
series had EGFR-overexpressing tumours and that this
feature was significantly associated with biochemical
relapse. Of the 13 tumours harbouring an EGFR muta-
tion, all belonged to the high Gleason Score group. Of
the identified mutations, some have been previously
shown to predict the antitumor activity of small molecule
tyrosine-kinase inhibitors. Further investigations on the
novel mutations that we have identified may reveal new
therapeutic targets. Finally, we identified a gene list in
EGFR-mutated patients associated with EGFR expression.
Conclusions
Although obtained in a small series of PC patients, our
findings suggest that accurate definition of the EGFR
Figure 5 Cluster analysis applied to 8 EGFR-mutated samples
using the 29-gene signature distinguished two classes. On the
left branch, EGFRlow samples and on the right branch EGFRhigh
samples.
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status could improve prognostic stratification and sug-
gests a possible role of EGFR-directed therapies in PC
patients.
Additional material
Additional file 1: Table S1. Clinical pathological characteristics and
EGFR status in PC patients
Additional file 2: Table S2. 79-gene signature (40 up-regulated and 39
down-regulated) distinguishing EGFRhigh/mutated samples from
EGFRhigh/WT samples
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